Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 4.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.14 | - |
NAV | ₹29.48 | - |
Fund Started | 04 Dec 2015 | - |
Fund Size | ₹1208.05 Cr | - |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 37.65% | - |
3 Year | 19.20% | - |
5 Year | 26.12% | - |
1 Year
3 Year
5 Year
Equity | 94.61% | - |
Cash | 5.39% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.31% |
Aurobindo Pharma Ltd. | 8.57% |
Lupin Ltd. | 7.43% |
Dr. Reddy's Laboratories Ltd. | 6.48% |
Cipla Ltd. | 6.29% |
Divi's Laboratories Ltd. | 5.12% |
Fortis Healthcare Ltd. | 4.42% |
Zydus Lifesciences Ltd. | 3.91% |
Alkem Laboratories Ltd. | 3.60% |
Apollo Hospitals Enterprise Ltd. | 3.42% |
Name | Meeta Shetty | - |
Start Date | 09 Nov 2018 | - |
Name
Start Date
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | - |
Launch Date | 04 Dec 2015 | - |
Description
Launch Date